Clinical Trials

PhaseBio is exploring the potential benefit of our investigational therapies in clinical trials, in order to confirm their mechanisms of action in humans, to investigate their side effects and to understand the characteristics of those patients most likely to benefit.

Our lead therapy, PB1046, is being currently evaluated in an exploratory trial in subjects with PAH, with a larger Phase 2 trial expected to initiate in mid-2018.

We are also conducting a Phase 1 single ascending dose trial evaluating the safety, tolerability, pharmacokinetics and pharmacodynamics of intravenous PB2452, our ticagrelor reversal agent, in healthy volunteers.

PhaseBio strives to work closely with patients and the scientific and regulatory communities to rapidly advance our pipeline and to identify new therapeutic applications that may benefit from our ELP biopolymer technology.